Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Stiripentol Combined With Other Antiepileptic Therapies Has Long-term Effectiveness, Study Says

Stiripentol combined with two other antiepileptic medicines seems to be an effective strategy to improve long-term seizure frequency in Dravet syndrome patients. The study that contains that finding, “Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study” was published in the journal Developmental Medicine & Child Neurology.

Epidiolex Seen in Phase 3 Trial to Significantly Lessen Drop Seizures in Rare Form of Childhood Epilepsy, Study Reports

GW Pharmaceuticals has published positive results of its Phase 3 trial testing Epidiolex, the company’s cannabis-based oral therapy, in people with treatment-resistent Lennox-Gastaut syndrome (LGS). The results, published in the journal The Lancet, also carry promise for Dravet syndrome, another rare and difficult-to-treat epilepsy, as this therapy is currently…

Measuring Brain Activity Pattern May Help Identify More Effective Anti-epileptic Therapies

Incorporating brain activity pattern analysis in chemical compounds screenings for Dravet syndrome and other epilepsies can help predict therapies’ effectiveness and minimize chances for off-target effects. That finding comes from the study “Brain activity patterns in high-throughput electrophysiology screen predict both drug efficacies and side effects,” which was published…

FDA to Give GW Pharmaceuticals’ Cannabis-based Therapy for Dravet Syndrome a Priority Review

The U.S. Food and Drug Administration will give priority review to a New Drug Application that GW Pharmaceuticals submitted for its cannabis-based therapy for two difficult-to-treat epilepsies that appear in childhood. U.S. regulators” decision to review the application on an accelerated timetable follows GW’s submission  of a Marketing Authorization Application to…